Bliss GVS Pharma Limited — Results, 30-01-2025: Integrated Filing- Financial

Bliss GVS Pharma Limited has announced a board meeting on January 28, 2025, to discuss the Integrated Financial Filing for the quarter and nine months ending December 31, 2024. For this period, total income stood at ₹19,125.43 cr, with a net profit of ₹2,105.25 cr. Noteworthy is the recognition of exceptional items due to impaired investments, amounting to ₹4,108.61 cr in standalone and ₹2,919.61 cr in consolidated results for the previous year. This update may cause mixed investor sentiment, highlighting potential risks from past investments while presenting a stable revenue outlook.